BofA analyst Jason Gerberry raised the firm’s price target on Merck (MRK) to $132 from $124 and keeps a Buy rating on the shares. Post Q4, the firm reduced its 2026 sales and EPS estimates to reflect greater conservatism around some loss of exclusivity products, U.S. Gardasil sales and Lagevrio, but increased outyear forecasts 2%-3% as it now includes MK-1406 for influenza in its forecast, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck price target raised to $100 from $95 at Bernstein
- Merck price target raised to $120 from $115 at Citi
- Merck price target raised to $135 from $125 at Wells Fargo
- Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited
- Merck Earnings Call Balances Pressure and Pipeline